• Complain

Carreyrou John - Bad Blood: Secrets and Lies in a Silicon Valley Startup

Here you can read online Carreyrou John - Bad Blood: Secrets and Lies in a Silicon Valley Startup full text of the book (entire story) in english for free. Download pdf and epub, get meaning, cover and reviews about this ebook. City: United States, year: 2018;2019, publisher: Alfred A. Knopf, genre: Detective and thriller. Description of the work, (preface) as well as reviews are available. Best literature library LitArk.com created for fans of good reading and offers a wide selection of genres:

Romance novel Science fiction Adventure Detective Science History Home and family Prose Art Politics Computer Non-fiction Religion Business Children Humor

Choose a favorite category and find really read worthwhile books. Enjoy immersion in the world of imagination, feel the emotions of the characters or learn something new for yourself, make an fascinating discovery.

No cover

Bad Blood: Secrets and Lies in a Silicon Valley Startup: summary, description and annotation

We offer to read an annotation, description, summary or preface (depends on what the author of the book "Bad Blood: Secrets and Lies in a Silicon Valley Startup" wrote himself). If you haven't found the necessary information about the book — write in the comments, we will try to find it.

A purposeful life -- The gluebot -- Apple envy -- Goodbye East Paly -- The childhood neighbor -- Sunny -- Dr. J -- The miniLab -- The wellness play -- Who is LTC Shoemaker? -- Lighting a Fuisz -- Ian Gibbons -- ChiatDay -- Going live -- Unicorn -- The grandson -- Fame -- The Hippocratic Oath -- The tip -- The ambush -- Trade secrets -- La mattanza -- Damage control -- The empress has no clothes -- Epilogue.;In 2015, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup unicorn promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmess worth at an estimated $4.5 billion. There was just one problem: The technology didnt work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When John Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the companys value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.--Publishers description.

Carreyrou John: author's other books


Who wrote Bad Blood: Secrets and Lies in a Silicon Valley Startup? Find out the surname, the name of the author of the book and a list of all author's works by series.

Bad Blood: Secrets and Lies in a Silicon Valley Startup — read online for free the complete book (whole text) full work

Below is the text of the book, divided by pages. System saving the place of the last page read, allows you to conveniently read the book "Bad Blood: Secrets and Lies in a Silicon Valley Startup" online for free, without having to search again every time where you left off. Put a bookmark, and you can go to the page where you finished reading at any time.

Light

Font size:

Reset

Interval:

Bookmark:

Make
THIS IS A BORZOI BOOK PUBLISHED BY ALFRED A KNOPF Copyright 2018 by John - photo 1
THIS IS A BORZOI BOOK PUBLISHED BY ALFRED A KNOPF Copyright 2018 by John - photo 2

THIS IS A BORZOI BOOK PUBLISHED BY ALFRED A. KNOPF

Copyright 2018 by John Carreyrou

All rights reserved. Published in the United States by Alfred A. Knopf, a division of Penguin Random House LLC, New York, and distributed in Canada by Random House of Canada, a division of Penguin Random House Canada Limited, Toronto.

www.aaknopf.com

Knopf, Borzoi Books, and the colophon are registered trademarks of Penguin Random House LLC.

Library of Congress Cataloging-in-Publication Data

Names: Carreyrou, John, author.

Title: Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou.

Description: First Edition. | New York : Knopf, 2018.

Identifiers: LCCN 2018000263 | ISBN 9781524731656 (hardback) | ISBN 9781524731663 (ebook)

Subjects: LCSH : Theranos (Firm)History. | Hematologic equipment industryUnited States. | FraudUnited States. | BISAC : BUSINESS & ECONOMICS / Entrepreneurship. | BUSINESS & ECONOMICS / Finance. | TECHNOLOGY & ENGINEERING / Biomedical.

Classification: LCC HD 9995. H 423 U 627 2018 | DDC 338.7/681761dc23 LC record available at https://lccn.loc.gov/2018000263

Ebook ISBN9781524731663

Cover design by Tyler Comrie

v5.2_r1

ep

Contents

For Molly, Sebastian, Jack, and Francesca

Authors Note

This book is based on hundreds of interviews with more than 150 people, including more than sixty former Theranos employees. Most of the men and women who appear as characters in the narrative do so under their real names, but some asked that I shield their identities, either because they feared retribution from the company, worried that they might be swept up in the Justice Departments ongoing criminal investigation, or wanted to guard their privacy. In the interest of getting the most complete and detailed rendering of the facts, I agreed to give these people pseudonyms. However, everything else I describe about them and their experiences is factual and true.

Any quotes I have used from emails or documents are verbatim and based on the documents themselves. When I have attributed quotes to characters in dialogues, those quotes are reconstructed from participants memories. Some chapters rely on records from legal proceedings, such as deposition testimony. When thats the case, I have identified those records at length in the notes section at the end of the narrative.

In the process of writing this book, I reached out to all of the key figures in the Theranos saga and offered them the opportunity to comment on any allegations concerning them. Elizabeth Holmes, as is her right, declined my interview requests and chose not to cooperate with this account.

Prologue

November 17, 2006

Tim Kemp had good news for his team.

The former IBM executive was in charge of bioinformatics at Theranos, a startup with a cutting-edge blood-testing system. The company had just completed its first big live demonstration for a pharmaceutical company. Elizabeth Holmes, Theranoss twenty-two-year-old founder, had flown to Switzerland and shown off the systems capabilities to executives at Novartis, the European drug giant.

Elizabeth called me this morning, Kemp wrote in an email to his fifteen-person team. She expressed her thanks and said that, it was perfect! She specifically asked me to thank you and let you all know her appreciation. She additionally mentioned that Novartis was so impressed that they have asked for a proposal and have expressed interest in a financial arrangement for a project. We did what we came to do!

This was a pivotal moment for Theranos. The three-year-old startup had progressed from an ambitious idea Holmes had dreamed up in her Stanford dorm room to an actual product a huge multinational corporation was interested in using.

Word of the demos success made its way upstairs to the second floor, where senior executives offices were located.

One of those executives was Henry Mosley, Theranoss chief financial officer. Mosley had joined Theranos eight months earlier, in March 2006. A rumpled dresser with piercing green eyes and a laid-back personality, he was a veteran of Silicon Valleys technology scene. After growing up in the Washington, D.C., area and getting his MBA at the University of Utah, hed come out to California in the late 1970s and never left. His first job was at chipmaker Intel, one of the Valleys pioneers. Hed later gone on to run the finance departments of four different tech companies, taking two of them public. Theranos was far from his first rodeo.

What had drawn Mosley to Theranos was the talent and experience gathered around Elizabeth. She might be young, but she was surrounded by an all-star cast. The chairman of her board was Donald L. Lucas, the venture capitalist who had groomed billionaire software entrepreneur Larry Ellison and helped him take Oracle Corporation public in the mid-1980s. Lucas and Ellison had both put some of their own money into Theranos.

Another board member with a sterling reputation was Channing Robertson, the associate dean of Stanfords School of Engineering. Robertson was one of the stars of the Stanford faculty. His expert testimony about the addictive properties of cigarettes had forced the tobacco industry to enter into a landmark $6.5 billion settlement with the state of Minnesota in the late 1990s. Based on the few interactions Mosley had had with him, it was clear Robertson thought the world of Elizabeth.

Theranos also had a strong management team. Kemp had spent thirty years at IBM. Diane Parks, Theranoss chief commercial officer, had twenty-five years of experience at pharmaceutical and biotechnology companies. John Howard, the senior vice president for products, had overseen Panasonics chip-making subsidiary. It wasnt often that you found executives of that caliber at a small startup.

It wasnt just the board and the executive team that had sold Mosley on Theranos, though. The market it was going after was huge. Pharmaceutical companies spent tens of billions of dollars on clinical trials to test new drugs each year. If Theranos could make itself indispensable to them and capture a fraction of that spending, it could make a killing.

Elizabeth had asked him to put together some financial projections she could show investors. The first set of numbers hed come up with hadnt been to her liking, so hed revised them upward. He was a little uncomfortable with the revised numbers, but he figured they were in the realm of the plausible if the company executed perfectly. Besides, the venture capitalists startups courted for funding knew that startup founders overstated these forecasts. It was part of the game. VCs even had a term for it: the hockey-stick forecast. It showed revenue stagnating for a few years and then magically shooting up in a straight line.

The one thing Mosley wasnt sure he completely understood was how the Theranos technology worked. When prospective investors came by, he took them to see Shaunak Roy, Theranoss cofounder. Shaunak had a Ph.D. in chemical engineering. He and Elizabeth had worked together in Robertsons research lab at Stanford.

Shaunak would prick his finger and milk a few drops of blood from it. Then he would transfer the blood to a white plastic cartridge the size of a credit card. The cartridge would slot into a rectangular box the size of a toaster. The box was called a reader. It extracted a data signal from the cartridge and beamed it wirelessly to a server that analyzed the data and beamed back a result. That was the gist of it.

Next page
Light

Font size:

Reset

Interval:

Bookmark:

Make

Similar books «Bad Blood: Secrets and Lies in a Silicon Valley Startup»

Look at similar books to Bad Blood: Secrets and Lies in a Silicon Valley Startup. We have selected literature similar in name and meaning in the hope of providing readers with more options to find new, interesting, not yet read works.


Reviews about «Bad Blood: Secrets and Lies in a Silicon Valley Startup»

Discussion, reviews of the book Bad Blood: Secrets and Lies in a Silicon Valley Startup and just readers' own opinions. Leave your comments, write what you think about the work, its meaning or the main characters. Specify what exactly you liked and what you didn't like, and why you think so.